West Pharmaceutical Services (WST) Payables (2009 - 2026)

West Pharmaceutical Services (WST) has reported Payables for 18 consecutive years, with $252.7 million the latest figure, recorded in Q2 2026.

• Quarterly Payables rose 5.73% year-over-year to $252.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $252.7 million (up 5.73% YoY) and the FY2025 annual result came in at $253.7 million, up 6.02% from the prior year.
• Payables steadied at $252.7 million in Q2 2026 per WST's latest filing, from $252.3 million in the prior quarter.
• Over the last five years, Payables for WST reached as high as $376.4 million in Q4 2023 and fell as low as $188.9 million in Q3 2022.
• A 5-year average of $263.0 million and a median of $252.5 million in 2026 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables soared 72.98% — and 2025, when it plunged 38.85%.
• Year by year, Payables stood at $217.6 million in 2022, then surged by 72.98% to $376.4 million in 2023, then sank by 36.42% to $239.3 million in 2024, then increased by 6.02% to $253.7 million in 2025, then decreased by 0.39% to $252.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $252.7 million, $252.3 million, and $253.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.